Green light for Perjeta/Herceptin combo
Roche group Genentech has secured approval of Perjeta in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment of a specific type of early breast cancer in the US.
Read More
Tag: APHINITY
- R1 Therapeutics begins global phase 2b trial of AP306 for hyperphosphatemia
- Mission Therapeutics divests MTX652 to Dimerix in deal worth up to $292 million
- Nouscom to present re‑treatment data in Lynch Syndrome at ESMO 2026
- ViiV Healthcare to unveil new HIV treatment data at AIDS 2026
- Jasper Therapeutics merges with Kira Pharmaceuticals
